What are the limitations of innate immune system activation in immunotherapeutic targeting in pediatric oncology?

Updated: Mar 20, 2018
  • Author: Crystal L Mackall, MD; Chief Editor: Jennifer Reikes Willert, MD  more...
  • Print


Although innate immune effectors can clearly mediate antitumor effects, elements of innate immunity may also contribute to tumor growth. Much recent interest has been focused on the interaction between inflammation and carcinogenesis. Especially in adult carcinomas, chronic inflammation can give rise to cancer, whereas anti-inflammatory therapies can prevent cancer.

Thus, although specific activation of innate effectors (eg, monocytes, macrophages, eosinophils) can induce potent killing of tumor cells, [28, 1, 29, 30] ample evidence also implicates tissue macrophages as contributors to the immunosuppressive microenvironment within tumors themselves and, thus, potential contributors to tumor growth.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!